Misinterpretation of trial evidence on statin adverse effects may harm patients

European Journal of Preventive Cardiology

Volumn 22, Issue 4, 2015, Pages 492-493

  Golomb, Beatrice A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ADVERSE DRUG REACTION; ARTICLE; FATIGUE; HUMAN; META ANALYSIS (TOPIC); MUSCLE WEAKNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84924937497     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487314533085     Document Type: Article

References (14)

1. Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. Epub ahead of print 12 March 2014. DOI: 2047487314525531.
2. Golomb BA, Chan VT, Evans MA, et al. The older the better: Are elderly study participants more non-representative? A cross-sectional analysis of clinical trial and observational study samples. BMJ Open. 2012 ; 2:
3. Sinzinger H, Lupattelli G, Chehne F, et al. Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J Clin Pharm Ther. 2001 ; 26: 303-310
4. Golomb BA, Evans MA. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008 ; 8: 373-418
5. Golomb BA, Kwon EK, Koperski S, et al. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: An analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf. 2009 ; 32: 649-661
6. Golomb BA, Koperski S. Who becomes weak on statins? Effect modification exposed in a RCT by risk factor compounding. Circulation. 2013 ; 127: AP072 AP072
7. Golomb BA, Koperski S, White HL. Statins raise glucose preferentially among men who are older and at greater metabolic risk. Circulation. 2012 ; 125: A055 A055
8. Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial. Arch Intern Med. 2012 ; 172: 1180-1182
9. Golomb BA. Glucose rise on statins in older age: Adaptive protection against fatigue?. Circulation. 2013 ; 127: AP041 AP041
10. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008 ; 358: 252-260
11. Bero L, Oostvogel F, Bacchetti P, et al. Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others. PLoS Med. 2007 ; 4: e184 e184
12. Golomb BA. This is your brain on politics [recording]. Beyond belief series: Candles in the dark, 5 October 2008, The Science Network (tsntv.org), http://thesciencenetwork.org/programs/beyond-belief-candles-in-the-dark/beatrice-golomb (accessed 12 April 2014).
13. Harris G. Caustic government report deals blow to diabetes drug. New York Times, 9 July 2010. Available at: http://www.nytimes.com/2010/07/10/health/10diabetes.html?pagewanted=all&-r=0 (accessed 12 April 2014).
14. Golomb BA. The importance of monitoring statin adverse effects in statin, and other, clinical trials. Clin Invest. 2013 ; 3: 913-916